Tempest Therapeutics (TPST) Capital Expenditures (2012 - 2024)
Tempest Therapeutics (TPST) posted Capital Expenditures of $3000.0 for Q4 2024, down 80.0% sequentially from $15000.0 in Q3 2024, and down 57.14% YoY from $7000.0 in Q1 2024.
Tempest Therapeutics (TPST) Capital Expenditures (2012 - 2024) Analysis & Trends
Tempest Therapeutics has reported Capital Expenditures for 13 years, with the latest figure at $3000.0 in Q4 2024.
- Quarterly Capital Expenditures fell 57.14% year-over-year to $3000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $3000.0 (down 99.32% YoY) and the FY2024 annual result came in at $435000.0, up 155.88% from the prior year.
- Capital Expenditures eased to $3000.0 in Q4 2024 per TPST's latest filing, from $15000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $356000.0 in Q4 2022 and troughed at $3000.0 in Q1 2022.
- A 5-year average of $71157.9 and a median of $26000.0 in 2020 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 1433.33% in 2023, down 98.03% in 2023.
- Over 5 years, Capital Expenditures stood at $5000.0 in 2020, then jumped by 440.0% to $27000.0 in 2021, then surged by 1218.52% to $356000.0 in 2022, then tumbled by 98.03% to $7000.0 in 2023, then sank by 57.14% to $3000.0 in 2024.
- According to Business Quant data, Capital Expenditures over the past three periods registered $3000.0, $15000.0, and $249000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 3,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 249,000.00 |
| Jun 30, 2024 | 249,000.00 |
| Mar 31, 2024 | 168,000.00 |
| Mar 31, 2024 | 168,000.00 |
| Dec 31, 2023 | 7,000.00 |
| Dec 31, 2023 | 7,000.00 |
| Jun 30, 2023 | 117,000.00 |
| Jun 30, 2023 | 117,000.00 |
| Mar 31, 2023 | 46,000.00 |
| Mar 31, 2023 | 46,000.00 |
| Dec 31, 2022 | 356,000.00 |
| Dec 31, 2022 | 356,000.00 |
| Sep 30, 2022 | 108,000.00 |
| Sep 30, 2022 | 108,000.00 |
| Jun 30, 2022 | 95,000.00 |
| Jun 30, 2022 | 95,000.00 |